INO) and certain officers ... Inovio's lead product candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis ("RRP"), a life-long, rare disease of the respiratory tract ...
INO) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.